CIZ1B Biomarker Test for Early Lung Cancer Detection
Coming Soon to U.S. Clinical Settings
A Novel Blood-Based Immunoassay Supporting Earlier Clinical Decisions
The CIZ1B biomarker test is a breakthrough, minimally invasive ELISA-based immunoassay designed to detect early-stage lung cancer through a simple blood draw. Developed from more than 30 years of research into the CIZ1 gene and its role in cell cycle regulation, CIZ1B represents a promising new tool to aid in early detection, risk stratification, and surveillance in high-risk patients.
Test Performance
0%
Sensitivity for Stage I Lung Cancer
0%
Negative Predictive Value (NPV)
Analytical validation based on UK population studies
Preliminary U.S. clinical validation data forthcoming from ongoing clinical studies at NCI-designated cancer centers, including Moffitt Cancer Center and UT Health San Antonio MD Anderson Cancer Center